The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Results from a study on the combination of sonrotoclax and zanubrutinib in R/R MCL
Ramón Garcia Sanz, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain, presents results from the ongoing Phase I study (NCT04277637) of the combination of sonrotoclax, a BCL2 targeted agent, and zanubrutinib, a BTK inhibitor, for patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This oral-based therapy was administered in different dosages to 40 patients and led to a 90% overall response rate (ORR) and an 80% complete response (CR) rate, with very few adverse events (AEs). Following these promising results, the trial is being extended to include more patients. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
